Compare SoundHound AI Inc (SOUN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoundHound AI Inc vs State Street SPDR S&P Biotech ETF — how do they compare? SoundHound AI Inc trades at $5.39 (market cap $2.45B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 4.1× SoundHound AI Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SoundHound AI Inc for 23 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SOUN | XBI | |
|---|---|---|
Market Cap | $2.45B | $10.11B |
Volume | 16,881,989 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $21.40 | $169.55 |
52-Week Low | $5.52 | $104.99 |
Typical Hold Time | 23 Days | 38 Days |
Enterprise Value | $2.25B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoundHound AI (SOUN) trades at $5.395, down 4.17% today, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth ($169M in 2025, $203M projected for 2026) but deep net losses (-$14M in 2025, -$137M projected). Recent developments include expansion into banking AI agents and the OASYS Edge embedded architecture launch for vehicles and smart devices, positioning for voice AI market growth.
Outlook is mixed: analyst consensus is bullish (75% buy ratings, $9.33 target) on growth prospects, but high valuation (P/S 11.41) and persistent losses pose risks. Key opportunities include market expansion and strategic deals; risks center on profitability, integration challenges, and competitive pressures in the AI sector.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
